[Featured Stock] Daewon Pharmaceutical Rises on Budesonide FDA COVID-19 Treatment Efficacy Confirmation News

[Asia Economy Reporter Jang Hyowon] Daewon Pharmaceutical's stock price is on the rise. This is attributed to news that the ingredient 'budesonide' contained in products sold by Daewon Pharmaceutical has shown effectiveness in treating COVID-19.

As of 10 a.m. on the 15th, Daewon Pharmaceutical is trading at 18,200 KRW, up 4.0% compared to the previous trading day.

On the 12th (local time), a research team from Oxford University announced the results of the 'PRINCIPLE' clinical trial conducted over 28 days on 2,780 high-risk COVID-19 patients, revealing that the inhaled asthma treatment budesonide showed effectiveness in treating COVID-19.

According to the interim analysis, 32% of patients in the group receiving inhaled budesonide treatment twice daily for 14 days recovered, compared to 22% recovery in the group receiving only standard treatment during the same period.

Furthermore, budesonide demonstrated superior effectiveness in early-stage patients compared to existing COVID-19 treatments such as dexamethasone, and its safety has been proven in patients with asthma or chronic obstructive pulmonary disease (COPD), suggesting high potential for utilization.

Meanwhile, Daewon Pharmaceutical is selling Daewon Budesonide Vial, and companies approved by the Ministry of Food and Drug Safety for the budesonide ingredient include Daewon Pharmaceutical, Korea AstraZeneca, and Samchundang Pharmaceutical.

This content was produced with the assistance of AI translation services.